Diakonos Oncology has dosed the first patients in its Phase I/II DOC-RM clinical trial of DOC1021 (dubodencel) for refractory melanoma.

The post Diakonos Oncology doses first patients in DOC-RM trial appeared first on Clinical Trials Arena.